Supernus Pharmaceuticals (SUPN) Earning Somewhat Favorable Press Coverage, Report Shows

News headlines about Supernus Pharmaceuticals (NASDAQ:SUPN) have been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Supernus Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 46.5227310931129 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s rankings:

Shares of Supernus Pharmaceuticals (SUPN) opened at $42.75 on Wednesday. The company has a market cap of $2,190.00, a PE ratio of 38.86 and a beta of 1.17. Supernus Pharmaceuticals has a 1 year low of $23.10 and a 1 year high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The business had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm’s revenue was up 41.5% on a year-over-year basis. analysts anticipate that Supernus Pharmaceuticals will post 1.07 EPS for the current fiscal year.

SUPN has been the topic of several recent research reports. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 10th. FBR & Co initiated coverage on shares of Supernus Pharmaceuticals in a report on Thursday, October 19th. They set a “buy” rating and a $53.00 target price on the stock. Janney Montgomery Scott upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 target price on the stock in a report on Monday, December 4th. Stifel Nicolaus raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research report on Tuesday, November 7th. Finally, Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 23rd. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $49.90.

In related news, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total value of $2,178,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Victor Vaughn sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $42.04, for a total transaction of $630,600.00. Following the completion of the transaction, the vice president now directly owns 24,344 shares of the company’s stock, valued at $1,023,421.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 125,750 shares of company stock valued at $5,273,573. Insiders own 6.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Supernus Pharmaceuticals (SUPN) Earning Somewhat Favorable Press Coverage, Report Shows” was first published by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://baseballnewssource.com/markets/supernus-pharmaceuticals-supn-earning-somewhat-favorable-press-coverage-report-shows/1840842.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.